Bal pharma Limited has filed its mandatory regulatory confirmation with stock exchanges regarding compliance with SEBI (Depository Participant) Regulations for the quarter ended March 31, 2026. The pharmaceutical company submitted the confirmation as required under Regulation 74(5) of SEBI (DP) Regulations.

Regulatory Compliance Confirmation

The company confirmed that all details of securities dematerialized and rematerialized during the quarter ended March 31, 2026, have been furnished to stock exchanges where its equity shares are listed. This submission was completed within the prescribed time limits as mandated by regulatory requirements.

Certificate Processing Details

Bal Pharma Limited confirmed that share certificates received for dematerialization have been properly processed according to regulatory standards. The company stated that certificates were mutilated and cancelled after due verification, with the depository's name substituted in records as the registered owner within 15 days of certificate receipt.

Communication and Authorization

The confirmation was digitally signed by Shailesh Siroya, serving as the authorized signatory for Bal Pharma Limited. The communication was addressed to both National Stock Exchange of India Limited and BSE Limited in Mumbai, with copies sent to National Securities Depository Limited and Central Depository Services (India) Limited.

The confirmation was dated April 6, 2026, and sent from the company's corporate office located at 5th Floor, H. M. Narayan Complex, Palace Road, Bangalore. This regulatory filing demonstrates the company's adherence to SEBI's depository participant regulations and maintains transparency with stock exchanges and depositories.

Bal Pharma Limited has delivered impressive financial performance in Q3FY26, demonstrating strong operational efficiency and growth momentum in the pharmaceutical sector. The company's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, during their meeting held on February 11, 2026.

Board Meeting Outcome and Regulatory Compliance

The Board of Directors meeting commenced at 5:00 PM and concluded at 6:15 PM on February 11, 2026, where they approved the unaudited standalone and consolidated financial results. The company has filed the outcome under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full regulatory compliance.

Strong Quarterly Performance

The company's Q3FY26 standalone results showcase remarkable growth across key financial metrics. Net profit witnessed a substantial surge of 181.84% year-on-year, rising from ₹69.07 lakhs in Q3FY25 to ₹194.62 lakhs in Q3FY26. This exceptional performance reflects the company's improved operational efficiency and strategic execution.

Nine-Month Performance Analysis

The nine-month period ended December 31, 2025, continued to reflect positive business trends. Revenue from operations reached ₹22,697.94 lakhs, marking a 2.84% increase from ₹22,071.28 lakhs in the corresponding period of the previous year. Net profit for the nine-month period stood at ₹305.10 lakhs, representing a healthy 39.15% growth compared to ₹219.26 lakhs in the same period last year.

Consolidated Results Highlight Group Performance

The consolidated financial results demonstrate the overall strength of Bal Pharma Limited and its subsidiaries. Consolidated revenue from operations for Q3FY26 reached ₹8,768.97 lakhs compared to ₹7,315.44 lakhs in Q3FY25. The consolidated net profit attributable to equity holders of the parent company stood at ₹177.99 lakhs in Q3FY26, significantly higher than ₹48.12 lakhs in the corresponding quarter of the previous year.

Earnings Per Share and Capital Structure

The company's earnings per share (EPS) performance reflects the strong bottom-line growth. Basic and diluted EPS for Q3FY26 stood at ₹1.22 compared to ₹0.43 in Q3FY25. For the nine-month period, EPS reached ₹1.92 versus ₹1.38 in the previous year. The paid-up equity share capital remained stable at ₹1,592.09 lakhs with a face value of ₹10 per share.

Regulatory Compliance and Audit Opinion

The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. The statutory auditors SSJNB & Co issued an unmodified opinion on both standalone and consolidated financial results, confirming the accuracy and compliance of the financial statements. The company operates primarily in the pharmaceuticals segment and maintains its registered office at Bommasandra Industrial Area, Bangalore.